However, the effect of vemurafenib in the treatment of metastatic BRAF mutated colorectal cancer is less potent than in BRAFV600E melanoma, and its clinical efficacy as monotherapy in BRAF mutant metastatic colorectal cancer is reduced due to the high incidence of fast-developing chemoresistance. The gene discussed is BRAF; the disease is melanoma.